Tay Tricia, Somasundaram Nagavalli, Lim Cindy, Khoo Lay Poh, Goh Allan Zhi Kai, Lee Yuh Shan, Liu Xin, Tao Miriam, Quek Richard, Farid Mohamad, Poon Eileen, Chan Jason Y S, Chang Esther W Y, Yang Valerie S W, Goh Yeow Tee, Tan Daryl, Diong Colin, Grigoropoulos Nicholas F, Nagarajan Chandramouli, Poon Michelle, de Mel Sanjay, Jeyasekharan Anand, Chan Esther H L, Lee Joanne, Chee Yen Lin, Lim Soon Thye, Tang Tiffany
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Division of Clinical Trials & Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore.
Cancer Rep (Hoboken). 2022 Sep;5(9):e1552. doi: 10.1002/cnr2.1552. Epub 2022 Apr 28.
Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited.
We performed a retrospective analysis to estimate outcomes of ICE-treated PTCL and NKTL patients at three tertiary cancer centres in Singapore.
Patients were identified through lymphoma databases from National Cancer Centre Singapore (NCCS), National University Hospital, Singapore (NUHS), and Singapore General Hospital (SGH). Responses and survival outcomes were determined from electronic medical records. A total of 75 patients with a median age of 50 were included. ICE was used as first-line treatment in 14 patients (19%) and as subsequent lines of treatment in 61 patients (81%). The overall response rates (ORR) for all patients was 63% (40% complete response [CR]). The ORR and CR in the first line were 86% and 64% respectively. At a median follow-up duration of 71.0 months, the median progression-free (PFS) and overall survival (OS) for all patients were 4.4 months (95%CI, 2.7-6.0) and 16 months (95%CI, 8.3-45.4) respectively.
In summary, ICE showed high ORR but poor PFS in relapsed/refractory PTCL and NKTL. ORR of ICE in the first line setting appears better than real-world CHOP data and warrants further study.
关于接受异环磷酰胺、卡铂和依托泊苷（ICE）治疗的外周T细胞淋巴瘤（PTCL）和自然杀伤/T细胞淋巴瘤（NKTL）患者的当代数据有限。
我们进行了一项回顾性分析，以评估新加坡三个三级癌症中心接受ICE治疗的PTCL和NKTL患者的预后。
通过新加坡国立癌症中心（NCCS）、新加坡国立大学医院（NUHS）和新加坡总医院（SGH）的淋巴瘤数据库识别患者。从电子病历中确定反应和生存结果。共纳入75例患者，中位年龄为50岁。14例患者（19%）将ICE用作一线治疗，61例患者（81%）将其用作后续治疗线。所有患者的总缓解率（ORR）为63%（完全缓解[CR]率为40%）。一线治疗的ORR和CR分别为86%和64%。在中位随访71.0个月时，所有患者的中位无进展生存期（PFS）和总生存期（OS）分别为4.4个月（95%CI，2.7 - 6.0）和16个月（95%CI，8.3 - 45.4）。
总之，ICE在复发/难治性PTCL和NKTL中显示出高ORR但PFS较差。ICE在一线治疗中的ORR似乎优于真实世界的CHOP数据，值得进一步研究。
